Vilanterol Trifenatate + Fluticasone Furoate + Umeclidinium Bromide
Indications
Vilanterol Trifenatate + Fluticasone Furoate + Umeclidinium Bromide is used for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). It is also used for the maintenance treatment of asthma in patients aged 18 years and older. Limitation of use: it is not indicated for relief of acute bronchospasm.
⚠️ Always consult a registered physician before taking any medicine.
Pharmacology
This capsule contains an inhalation powder that delivers three medicines by oral inhalation: fluticasone furoate (an ICS), umeclidinium (an anticholinergic) and vilanterol (a LABA). The effects of beta 2-adrenoceptor agonists such as vilanterol come, at least in part, from stimulating intracellular adenyl cyclase. This enzyme catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3, 5 -adenosine monophosphate (cyclic AMP). Higher cyclic AMP levels relax the bronchial smooth muscle and inhibit the release of mediators of immediate hypersensitivity from cells, especially from mast cells. The precise way fluticasone furoate affects COPD and asthma symptoms is not known. Inflammation is an important part of how COPD and asthma develop, and corticosteroids have been shown to act on many cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and many mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) involved in inflammation. Umeclidinium is a long-acting muscarinic antagonist, often called an anticholinergic. It has similar affinity for the muscarinic receptor subtypes M1 to M5. In the airways, it works by inhibiting the M3 receptor at the smooth muscle, which leads to bronchodilation.
Dosage Reference
⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.
Side Effects & Interactions
Side Effects
No side-effect data recorded yet.